On December 14, 2016, Jeffrey Glazer and Jason Malek, the former CEO and President, respectively, of a generic pharmaceutical company were charged in the Eastern District of Pennsylvania for their roles in conspiracies to fix prices, rig bids, and allocate customers to particular generic drugs, including the antibiotic doxycycline hyclate and the diabetes medication glyburide.  The doxycycline hyclate conspiracy allegedly took place from as early as April 2013 until at least December 2015, while the glyburide conspiracy took place from as early as April 2014 until December 2015.  The charges are a result of an ongoing Antitrust Division investigation into price fixing, bid rigging, and other anticompetitive conduct in the generic pharmaceutical industry.  United States v. Glazer, 2:16-cr-00506 (E.D. Pa.); United States v. Malek, 2:16-cr-00508 (E.D. Pa.). DOJ Press Release